Regenxbio Inc. (NASDAQ:RGNX) shares traded up 2.9% on Tuesday . The company traded as high as $12.94 and last traded at $12.62, with a volume of 204,954 shares traded. The stock had previously closed at $12.27.

A number of research analysts have weighed in on the company. Zacks Investment Research upgraded Regenxbio from a “sell” rating to a “hold” rating in a report on Friday. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a report on Monday, August 22nd. Finally, Piper Jaffray Cos. set a $25.00 price target on Regenxbio and gave the stock a “buy” rating in a research note on Thursday, August 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $26.75.

The company’s market cap is $322.61 million. The firm has a 50 day moving average of $9.70 and a 200-day moving average of $10.91.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Analysts forecast that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC boosted its stake in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned 2.84% of Regenxbio worth $12,393,000 as of its most recent SEC filing.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.